Filing Flows › Biolargo (BLGO) › Q4 2024
Biolargo (BLGO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Biolargo (BLGO) reported revenue of $3.7M for the fourth quarter 2024 (Q4 2024), -16% from a year earlier and -16% from the quarter before. Operating margin was -44.2%, net loss $1.7M (47.4% of revenue).
Biolargo, Q4 2024: revenue $3.7M (-16% year over year), operating margin -44.2%, net loss $1.7M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | -16% | -16% |
| Operating profit | −$1.6M | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | −$1.9M | — | — |
What changed
Revenue was $3.7M in Q4 2024, down 16% year over year and down 16% from the previous quarter. Product was the largest line at 92% of revenue.
Gross margin was 47.9%, up 0.1 points from a year earlier. Operating costs exceeded revenue by $1.6M, an operating margin of -44.2%. Operating expenses grew 9% against a revenue fall of 16%. The fastest-growing cost line was Research & development (+80%). The quarter ended with a net loss of $1.7M, wider than the previous quarter's $1.1M loss. Minority interests bore $718K of it: to shareholders the quarter was a loss of $1.0M.
Operating cash flow was −$1.9M. Non-cash charges added back $40K of depreciation and $799K of share-based compensation. Working capital and other items used $1.0M.
Questions
What was Biolargo's revenue in the fourth quarter 2024?
Biolargo (BLGO) reported revenue of $3.7M for the fourth quarter 2024 (Q4 2024), -16% from a year earlier and -16% from the quarter before.
Was Biolargo profitable in the fourth quarter 2024?
Operating loss was $1.6M (-44.2% of revenue) and net loss $1.7M.
Source: Biolargo 10-K on SEC EDGAR.